Diseases
Companies
Products
Productz
Mechanisms of Action
Sites
hepenofovir
/
Xi’an XinTong Pharma
Welcome,
Profile
Billing
Logout
Diseases
Trials
Trials
News
|
|||||||||
hepenofovir
/
Xi'an XinTong Pharma
New P1/2 trial:
HTS: A Phase Ic/IIb Study to Evaluate the Efficacy?Safety and Pharmacokinetics of HST in Patients With CHB
(clinicaltrials.gov) - Nov 8, 2023
P1/2
, N=48, Recruiting,
Sponsor: Xi'an Xintong Pharmaceutical Research Co.,Ltd.
||
||||||||
hepenofovir
/
Xi'an XinTong Pharma
P1 data, PK/PD data, Journal:
First-In-Human Study on Pharmacokinetics, Safety, and Tolerability of Single and Multiple Escalating Doses of Hepenofovir, a Novel Hepatic Targeting Prodrug of Tenofovir in Healthy Chinese Subjects.
(Pubmed Central) - Jun 8, 2022
Hepenofovir has shown a favorable safety and PK profile, which support the further evaluation of its safety and efficacy in CHB patients. Clinical trial registration number: The trial is registered at Chinese Clinical Trial website (http://www.chinadrugtrials.org.cn/index.html # CTR20191953).
|
|||||||||
hepenofovir
/
Xi'an XinTong Pharma
New P1 trial:
A Study to Investigate the Safety, Tolerability, Pharmacokinetics of Single and Multiple Doses of Hepenofovir Fumarate Tablets in Healthy Volunteers.
(clinicaltrials.gov) - Feb 19, 2020
P1
, N=69, Not yet recruiting,
Sponsor: Xi'an Xintong Pharmaceutical Research Co.,Ltd.